Related Experiment Video

Updated: Mar 1, 2026

A 3D Organotypic Melanoma Spheroid Skin Model
08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

16.7K

Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma

Su Yin Lim1,2, Alexander M Menzies2,3,4, Helen Rizos1,2

  • 1Faculty of Medicine and Health Sciences, Macquarie University, Sydney, New South Wales, Australia.

Cancer
|May 26, 2017
PubMed

Insights

Targeted therapies for BRAF-mutant melanoma show promise but often lead to resistance. Understanding resistance mechanisms is crucial for developing new strategies to improve patient outcomes in advanced melanoma.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Genetics

Background:

  • Driver mutations like BRAF and NRAS are common in melanoma.
  • These mutations activate key signaling pathways, including MAPK and PI3K/AKT.
  • Targeted therapies have transformed advanced melanoma treatment.

Purpose of the Study:

  • To review the efficacy of MAPK and PI3K/AKT pathway inhibitors in melanoma.
  • To detail the mechanisms of therapeutic resistance in melanoma.
  • To discuss strategies for overcoming drug resistance and improving patient outcomes.

Main Methods:

  • Literature review of targeted therapies for melanoma.
  • Analysis of molecular mechanisms underlying drug resistance.
  • Discussion of current and future treatment strategies.

Main Results:

  • Targeted inhibitors of the MAPK pathway have shown significant efficacy in BRAF-mutant melanoma.
  • Therapeutic resistance is a near-universal challenge, leading to disease progression within a year.
  • Multiple resistance mechanisms contribute to treatment failure.

Conclusions:

  • Despite initial success, resistance remains a major hurdle in advanced melanoma treatment.
  • Further research into resistance mechanisms is essential for developing more effective therapies.
  • Combining targeted approaches and understanding resistance pathways may improve long-term outcomes.
Keywords:
BRAF inhibitorsimmunotherapymelanomamitogen-activated protein kinase (MAPK) pathwaymitogen-activated protein kinase kinase (MEK) inhibitorsphosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) pathwaytargeted therapy

More Related Videos

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.6K
A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

3.0K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.2K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.2K